IL238116B - A process for preparing compounds for use in the treatment of cancer - Google Patents
A process for preparing compounds for use in the treatment of cancerInfo
- Publication number
- IL238116B IL238116B IL238116A IL23811615A IL238116B IL 238116 B IL238116 B IL 238116B IL 238116 A IL238116 A IL 238116A IL 23811615 A IL23811615 A IL 23811615A IL 238116 B IL238116 B IL 238116B
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- treatment
- making compounds
- compounds
- making
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713104P | 2012-10-12 | 2012-10-12 | |
| PCT/US2013/064866 WO2014059422A1 (en) | 2012-10-12 | 2013-10-14 | Novel process for making compounds for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL238116B true IL238116B (en) | 2018-06-28 |
Family
ID=49474740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL238116A IL238116B (en) | 2012-10-12 | 2015-04-02 | A process for preparing compounds for use in the treatment of cancer |
Country Status (31)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2671502T3 (es) | 2012-10-12 | 2018-06-06 | Exelixis, Inc. | Proceso novedoso para preparar compuestos para su uso en el tratamiento de cáncer |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
| EP4272735B1 (en) | 2015-06-30 | 2025-06-18 | Genentech, Inc. | Immediate-release tablets containing a drug and processes for forming the tablets |
| CN105330643B (zh) | 2015-12-09 | 2017-12-05 | 苏州明锐医药科技有限公司 | 卡比替尼的制备方法 |
| CN106045969B (zh) * | 2016-05-27 | 2019-04-12 | 湖南欧亚药业有限公司 | 一种卡比替尼的合成方法 |
| CA3032542A1 (en) | 2016-08-12 | 2018-02-15 | Genentech, Inc. | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor |
| KR20190061030A (ko) | 2016-09-29 | 2019-06-04 | 제넨테크, 인크. | Mek 억제제, pd-1 축 억제제 및 탁산을 사용한 조합 요법 |
| WO2020187674A1 (en) | 2019-03-15 | 2020-09-24 | Sandoz Ag | Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate |
| KR20230156731A (ko) | 2021-03-09 | 2023-11-14 | 제넨테크, 인크. | 뇌암 치료에 이용하기 위한 벨바라페닙 |
| WO2022216719A1 (en) | 2021-04-06 | 2022-10-13 | Genentech, Inc. | Combination therapy with belvarafenib and cobimetinib or with belvarafenib, cobimetinib, and atezolizumab |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1563587A (en) * | 1924-09-20 | 1925-12-01 | Raney Murray | Method of preparing catalytic material |
| US1628190A (en) * | 1926-05-14 | 1927-05-10 | Raney Murray | Method of producing finely-divided nickel |
| US1915473A (en) * | 1930-12-31 | 1933-06-27 | Raney Murray | Method of preparing catalytic material |
| US4510139A (en) | 1984-01-06 | 1985-04-09 | Sterling Drug Inc. | Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity |
| US5155110A (en) | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
| CA2186947A1 (en) | 1994-04-01 | 1995-10-12 | Kazuo Ueda | Oxime derivative and bactericide containing the same as active ingredients |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| WO1998037881A1 (en) | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| HUP0003731A3 (en) | 1997-07-01 | 2002-11-28 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
| ATE344791T1 (de) | 1997-07-01 | 2006-11-15 | Warner Lambert Co | 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren |
| US6974878B2 (en) | 2001-03-21 | 2005-12-13 | Symyx Technologies, Inc. | Catalyst ligands, catalytic metal complexes and processes using same |
| EP1140046A1 (en) | 1998-12-15 | 2001-10-10 | Warner-Lambert Company | Use of a mek inhibitor for preventing transplant rejection |
| WO2000035436A2 (en) | 1998-12-16 | 2000-06-22 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
| JP2002532570A (ja) | 1998-12-22 | 2002-10-02 | ワーナー−ランバート・カンパニー | 併用化学療法 |
| KR20000047461A (ko) | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
| JP2002534380A (ja) | 1999-01-07 | 2002-10-15 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤による喘息の治療 |
| HUP0104933A3 (en) | 1999-01-07 | 2003-12-29 | Warner Lambert Co | Antiviral method using mek inhibitors |
| US6545030B1 (en) | 1999-01-13 | 2003-04-08 | Warner-Lambert Company | 1-heterocycle substituted diarylamines |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| ES2252996T3 (es) | 1999-01-13 | 2006-05-16 | Warner-Lambert Company Llc | Derivados de bencenosulfonamida y su uso como inhibidores de mek. |
| CA2349180A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | Anthranilic acid derivatives |
| HRP20010524A2 (en) | 1999-01-13 | 2002-08-31 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors |
| KR20020015379A (ko) | 1999-07-16 | 2002-02-27 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 엠이케이 억제제를 사용하는 만성 동통의 치료방법 |
| HUP0202319A3 (en) | 1999-07-16 | 2004-12-28 | Warner Lambert Co | Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain |
| TR200200205T2 (tr) | 1999-07-16 | 2002-06-21 | Warner-Lambert Company | MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi |
| HUP0202623A3 (en) | 1999-07-16 | 2003-03-28 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
| HU230773B1 (hu) | 1999-09-17 | 2018-03-28 | Millennium Pharmaceuticals, Inc. | Benzamidok és rokon Xa faktor inhibitorok |
| BR0109188A (pt) | 2000-03-15 | 2003-03-18 | Warner Lambert Co | Diarilaminas 5-amida substituìdas como inibidores de mex |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| KR100773621B1 (ko) | 2000-07-19 | 2007-11-05 | 워너-램버트 캄파니 엘엘씨 | 4-요오도 페닐아미노 벤즈히드록삼산의 산소화 에스테르 |
| MXPA03001654A (es) * | 2000-08-25 | 2004-09-10 | Warner Lambert Co | Proceso para la elaboracion del acido n-aril-antranilico y sus derivados. |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| NZ518726A (en) | 2001-05-09 | 2004-06-25 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US20040039208A1 (en) * | 2001-07-20 | 2004-02-26 | Chen Michael Huai Gu | Process for making n-aryl-anthranilic acids and their derivatives |
| DE10141266A1 (de) | 2001-08-21 | 2003-03-06 | Syntec Ges Fuer Chemie Und Tec | Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden |
| US7085492B2 (en) | 2001-08-27 | 2006-08-01 | Ibsen Photonics A/S | Wavelength division multiplexed device |
| HUP0401967A2 (hu) | 2001-10-31 | 2005-01-28 | Pfizer Products Inc. | Nikotinsav-acetilkolin-receptor-agonisták alkalmazása nyugtalan láb szindróma kezelésére alkalmas gyógyszerkészítmények előállítására |
| CA2473545A1 (en) | 2002-01-23 | 2003-07-31 | Warner-Lambert Company Llc | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| DOP2003000556A (es) | 2002-01-23 | 2003-10-31 | Warner Lambert Co | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico. |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| CA2478374C (en) | 2002-03-13 | 2009-01-06 | Eli M. Wallace | N3 alkylated benzimidazole derivatives as mek inhibitors |
| CN1652792A (zh) | 2002-03-13 | 2005-08-10 | 阵列生物制药公司 | 作为mek抑制剂的n3烷基化苯并咪唑衍生物 |
| EP1515727A4 (en) | 2002-06-11 | 2009-04-08 | Merck & Co Inc | (HALO-BENZO CARBONYL) HETEROBICYCLIC P38 KINASE INHIBITION |
| GB0214268D0 (en) | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
| US20060094674A1 (en) | 2002-07-05 | 2006-05-04 | Neel Benjamin G | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| CA2517517C (en) | 2003-03-03 | 2012-12-18 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| TW200505834A (en) | 2003-03-18 | 2005-02-16 | Sankyo Co | Sulfamide derivative and the pharmaceutical composition thereof |
| JP2005162727A (ja) | 2003-03-18 | 2005-06-23 | Sankyo Co Ltd | スルファミド誘導体及びその医薬組成物 |
| GB0308185D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| WO2004113347A1 (en) | 2003-06-20 | 2004-12-29 | Celltech R & D Limited | Thienopyridone derivatives as kinase inhibitors |
| WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| US20050049276A1 (en) | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| WO2005009975A2 (en) | 2003-07-24 | 2005-02-03 | Warner-Lambert Company Llc | Benzimidazole derivatives as mek inhibitors |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US8084645B2 (en) | 2003-09-19 | 2011-12-27 | Chugai Seiyaku Kabushiki Kaisha | 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| UA84175C2 (ru) | 2003-11-19 | 2008-09-25 | Аррей Байофарма Инк. | Гетероциклические ингибиторы мэк и их применение |
| JP4527729B2 (ja) | 2003-12-08 | 2010-08-18 | エフ．ホフマン−ラ ロシュ アーゲー | 新規チアゾール誘導体 |
| MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| AR051248A1 (es) * | 2004-10-20 | 2007-01-03 | Applied Research Systems | Derivados de 3-arilamino piridina |
| WO2006061712A2 (en) | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| GEP20125456B (en) | 2005-10-07 | 2012-03-26 | Exelixis Inc | Azetidines as mek inhibitors for the treatment of proliferative diseases |
| WO2008021389A2 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| WO2008076415A1 (en) * | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| ES2671502T3 (es) | 2012-10-12 | 2018-06-06 | Exelixis, Inc. | Proceso novedoso para preparar compuestos para su uso en el tratamiento de cáncer |
| BR112016017648B1 (pt) | 2014-02-07 | 2021-01-19 | Sumitomo Chemical Company, Limited | método para produção de (r)-1,1,3-trimetil-4-aminoindano |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
-
2013
- 2013-10-14 ES ES13780303.7T patent/ES2671502T3/es active Active
- 2013-10-14 PE PE2015000485A patent/PE20151494A1/es active IP Right Grant
- 2013-10-14 JP JP2015536988A patent/JP6300042B2/ja active Active
- 2013-10-14 CR CR20200237A patent/CR20200237A/es unknown
- 2013-10-14 BR BR112015008113-4A patent/BR112015008113B1/pt active IP Right Grant
- 2013-10-14 TR TR2018/07861T patent/TR201807861T4/tr unknown
- 2013-10-14 CA CA2889466A patent/CA2889466C/en active Active
- 2013-10-14 HR HRP20180670TT patent/HRP20180670T1/hr unknown
- 2013-10-14 CN CN201380064338.7A patent/CN104837826B/zh active Active
- 2013-10-14 CN CN201810758236.XA patent/CN108948043B/zh active Active
- 2013-10-14 MA MA38085A patent/MA38085B1/fr unknown
- 2013-10-14 HK HK16101572.6A patent/HK1213567A1/zh unknown
- 2013-10-14 PE PE2019002024A patent/PE20191818A1/es unknown
- 2013-10-14 UA UAA201504532A patent/UA115455C2/uk unknown
- 2013-10-14 AU AU2013328929A patent/AU2013328929B2/en active Active
- 2013-10-14 SG SG11201502795VA patent/SG11201502795VA/en unknown
- 2013-10-14 EP EP13780303.7A patent/EP2909188B1/en active Active
- 2013-10-14 PL PL13780303T patent/PL2909188T3/pl unknown
- 2013-10-14 SI SI201331045T patent/SI2909188T1/en unknown
- 2013-10-14 MY MYPI2015000897A patent/MY186549A/en unknown
- 2013-10-14 IN IN3928DEN2015 patent/IN2015DN03928A/en unknown
- 2013-10-14 EA EA201590700A patent/EA030613B1/ru not_active IP Right Cessation
- 2013-10-14 NZ NZ706723A patent/NZ706723A/en unknown
- 2013-10-14 KR KR1020157012066A patent/KR102204520B1/ko active Active
- 2013-10-14 GE GEAP201313824A patent/GEP201706690B/en unknown
- 2013-10-14 MX MX2015004660A patent/MX372708B/es active IP Right Grant
- 2013-10-14 WO PCT/US2013/064866 patent/WO2014059422A1/en not_active Ceased
-
2015
- 2015-04-02 IL IL238116A patent/IL238116B/en active IP Right Grant
- 2015-04-08 ZA ZA2015/02349A patent/ZA201502349B/en unknown
- 2015-04-08 PH PH12015500785A patent/PH12015500785B1/en unknown
- 2015-04-10 MX MX2020005533A patent/MX2020005533A/es unknown
- 2015-04-12 SA SA515360271A patent/SA515360271B1/ar unknown
- 2015-04-13 CL CL2015000926A patent/CL2015000926A1/es unknown
- 2015-04-13 US US14/684,826 patent/US9771347B2/en active Active
- 2015-05-11 CR CR20150245A patent/CR20150245A/es unknown
-
2017
- 2017-08-25 US US15/686,333 patent/US10239858B2/en active Active
- 2017-12-06 JP JP2017234208A patent/JP2018052973A/ja not_active Withdrawn
-
2019
- 2019-02-08 US US16/271,215 patent/US10793541B2/en active Active
- 2019-08-08 PE PE2019001563A patent/PE20200387A1/es unknown
-
2020
- 2020-08-26 US US17/003,570 patent/US11414396B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267242B (en) | Cancer treatment | |
| GB2495841B (en) | Phytocannabinoids for use in the treatment of breast cancer | |
| GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
| SG11201501653RA (en) | Methods for the treatment of locally advanced breast cancer | |
| IL238400A (en) | Triazulophyrazines as brd4 inhibitors for use in cancer treatment | |
| EP2751267A4 (en) | METHOD FOR THE TREATMENT OF BREAST CANCER | |
| IL238116B (en) | A process for preparing compounds for use in the treatment of cancer | |
| PT2804599T (pt) | Terapêutica de associação para o tratamento de cancro | |
| IL230698A0 (en) | Use of preparations containing crizotinib to treat cancer | |
| PT3400943T (pt) | Compostos para serem utilizados no tratamendo de metástase no cérebro num doente com cancro da mama positivo para erbb2. | |
| EP2903644A4 (en) | TREATMENT OF CANCER | |
| GB201217892D0 (en) | Treatment of cancer | |
| SI2872176T1 (sl) | Karboranilporfirin za uporabo pri zdravljenju raka | |
| PL2855475T3 (pl) | Alfa-karboliny do leczenia nowotworu | |
| IL237229A0 (en) | Methods of treating cancer using lipoplatin | |
| GB201222563D0 (en) | Cancer treatment | |
| GB201217890D0 (en) | Treatment of cancer | |
| IL233495A0 (en) | Combination for cancer treatment | |
| GB201205449D0 (en) | Treatment process | |
| GB201208296D0 (en) | Treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |